In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ThromboGenics/Alcon's Jetrea gets strongest AMNOG endorsement yet from German HTA

This article was originally published in Scrip

Executive Summary

ThromboGenics/Alcon's Jetrea (ocriplasmin) for vitreomacular traction has won the strongest endorsement yet from German health technology appraisal institute IQWiG for a drug passing through the tough AMNOG pricing and reimbursement system. The institute thinks it offers "major" and "considerable" benefits over standard of care, which bodes well for the price that the firm will eventually be able to command in Germany.

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC022326

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel